BMGF HIV-1 Incidence

Determining recent infection across the globe is critical to more precisely target prevention resources and determine their effectiveness. Current incidence tests have an unacceptable level of false recents and in particular have overall poor performance with difficult to classify specimens such as viremia suppressed and antiretroviral treated. Thus, new immunological biomarkers of recent infection are needed in the current setting where treatment for all, including the newly diagnosed, is standard of care. The overall goal of this program is to identify novel combinations of antibody isotypes and subclasses paired with antigens that represent HIV-1 envelope diversity and transmitted sequences in order to provide measurements (presence/absence, concentration, avidity) that can be transformative in determining accurate HIV-1 incidence across the globe.